Caffeine occupancy of human cerebral A1 adenosine receptors: In vivo quantification with 18F-CPFPX and PET

Journal of Nuclear Medicine

Volumn 53, Issue 11, 2012, Pages 1723-1729

  Elmenhorst, David ^a   Meyer, Philipp T ^a,b   Matusch, Andreas ^a   Winz, Oliver H ^a   Bauer, Andreas ^a,c  

^a FORSCHUNGSZENTRUM JÜLICH   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Adenosine A1 receptor; Brain; Caffeine; CPFPX; Human; Positron emission tomography

Indexed keywords

8 CYCLOPENTYL 3 (3 FLUOROPROPYL) 1 PROPYLXANTHINE F 18; ADENOSINE A1 RECEPTOR; CAFFEINE; TRACER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BOLUS INJECTION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; HALF LIFE TIME; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; LIGAND BINDING; MALE; NORMAL HUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STEADY STATE;

ADULT; BRAIN; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, ADENOSINE A1; XANTHINES; YOUNG ADULT;

EID: 84868323978     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.105114     Document Type: Article

References (35)

1. Brunyé TT, Mahoney CR, Lieberman HR, Taylor HA. Caffeine modulates attention network function. Brain Cogn. 2010;72:181-188.
2. Suzuki F, Shimada J, Shiozaki S, et al. Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl) adenosine-induced cognitive disturbance. J Med Chem. 1993;36:2508-2518.
3. Prediger RD, Takahashi RN. Modulation of short-term social memory in rats by adenosine A1 and A2A receptors. Neurosci Lett. 2005;376:160-165.
4. Chen Y, Parrish TB. Caffeine dose effect on activation-induced BOLD and CBF responses. Neuroimage. 2009;46:577-583.
5. Landolt HP, Retey JV, Tonz K, et al. Caffeine attenuates waking and sleep electroencephalographic markers of sleep homeostasis in humans. Neuropsychopharmacology. 2004;29:1933-1939.
6. Landolt HP, Dijk DJ, Gaus SE, Borbely AA. Caffeine reduces low-frequency delta activity in the human sleep EEG. Neuropsychopharmacology. 1995;12:229-238.
7. Blanchard J, Sawers SJ. The absolute bioavailability of caffeine in man. Eur J Clin Pharmacol. 1983;24:93-98.
8. Arnaud MJ, Bracco I, Welsch C. Metabolism and distribution of labeled theophylline in the pregnant rat: impairment of theophylline metabolism by pregnancy and absence of a blood-brain barrier in the fetus. Pediatr Res. 1982;16:167-171.
9. Bonati M, Latini R, Galletti F, Young JF, Tognoni G, Garattini S. Caffeine disposition after oral doses. Clin Pharmacol Ther. 1982;32:98-106.
10. Liu X, Smith BJ, Chen C, et al. Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration. Drug Metab Dispos. 2006;34:1443-1447.
11. Lazarus M, Shen HY, Cherasse Y, et al. Arousal effect of caffeine depends on adenosine A2A receptors in the shell of the nucleus accumbens. J Neurosci. 2011;31:10067-10075.
12. Chen JF, Yu L, Shen HY, He JC, Wang X, Zheng R. What knock-out animals tell us about the effects of caffeine. J Alzheimers Dis. 2010;20(suppl 1):S17-S24.
13. Huang ZL, Qu WM, Eguchi N, et al. Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine. Nat Neurosci. 2005;8:858-859.
14. 18F]CPFPX and positron emission tomography. Neuroimage. 2003;19:1760-1769.
15. 18F-CPFPX, a novel adenosine A1 receptor ligand: in vitro autoradiography and high-resolution small animal PET. J Nucl Med. 2003;44:1682-1689.
16. 1-adenosine receptor antagonist for in vivo imaging. J Med Chem. 2002;45:5150-5156.
17. 11C]MPDX. Ann Nucl Med. 2003;17:511-515.
18. 18F]CPFPX and PET: an equilibrium approach. Neuroimage. 2005;24:1192-1204.
19. 18F]CPFPX: displacement studies in humans. Neuroimage. 2006;32:1100-1105.
20. 18F]CPFPX and PET. Eur J Nucl Med Mol Imaging. 2007;34:1061-1070.
21. 3H]CPFPX binding by adenosine and caffeine. Neurosci Lett. 2011;487:415-420.
22. Meyer PT, Bier D, Holschbach MH, Cremer M, Tellmann L, Bauer A. Image of the month: in vivo imaging of rat brain A1 adenosine receptor occupancy by caffeine. Eur J Nucl Med Mol Imaging. 2003;30:1440.
23. Mandel HG. Update on caffeine consumption, disposition and action. Food Chem Toxicol. 2002;40:1231-1234.
24. Brix G, Zaers J, Adam LE, et al. Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. J Nucl Med. 1997;38:1614-1623.
25. 18F]CPFPX and PET. J Cereb Blood Flow Metab. 2004;24:323-333.
26. Cunningham VJ, Rabiner EA, Slifstein M, Laruelle M, Gunn RN. Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. J Cereb Blood Flow Metab. 2010;30:46-50.
27. 11C]flumazenil and PET: application of the steady-state principle. J Cereb Blood Flow Metab. 1995;15:152-165.
28. 18F]CPFPX by CYP1A2: implications for bolus/infusion PET studies. Nucl Med Biol. 2006;33:891-898.
29. Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev. 1999;51:83-133.
30. 3H]NECA in rat striatal membranes. Mol Pharmacol. 1986; 29:331-346.
31. Fredholm BB, Lindstrom K. Autoradiographic comparison of the potency of several structurally unrelated adenosine receptor antagonists at adenosine A1 and A(2A) receptors. Eur J Pharmacol. 1999;380:197-202.
32. Laurienti PJ, Field AS, Burdette JH, Maldjian JA, Yen YF, Moody DM. Relationship between caffeine-induced changes in resting cerebral perfusion and blood oxygenation level-dependent signal. AJNR. 2003;24:1607-1611.
33. Koppelstaetter F, Poeppel TD, Siedentopf CM, et al. Does caffeine modulate verbal working memory processes? An fMRI study. Neuroimage. 2008;39:492-499.
34. Chen Y, Parrish TB. Caffeine's effects on cerebrovascular reactivity and coupling between cerebral blood flow and oxygen metabolism. Neuroimage. 2009;44:647-652.
35. Santos C, Costa J, Santos J, Vaz-Carneiro A, Lunet N. Caffeine intake and dementia: systematic review and meta-analysis. J Alzheimers Dis. 2010;20(suppl 1):S187-S204.